Producto añadido correctamente al carrito.

discount label
Bivalirudin
Ver en 3D

Biosynth logo

Bivalirudin

Ref. 3D-PP49896

1mg
248,00 €
10mg
292,00 €
100mg
481,00 €
Entrega estimada en Estados Unidos, el Viernes 27 de Diciembre de 2024

Información del producto

Nombre:
Bivalirudin
Descripción:

Peptide Bivalirudin is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using Bivalirudin include the following: Clot-targeted micellar formulation improves anticoagulation efficacy of bivalirudin ZG She , X Liu , VR Kotamraju, E Ruoslahti - ACS nano, 2014 - ACS Publicationshttps://pubs.acs.org/doi/abs/10.1021/nn502947b A systematic review and meta-analysis of bivalirudin application in peripheral endovascular procedures Y Hu , AY Liu, L Zhang, X Wu, S Shi, JR Elmore - Journal of Vascular , 2019 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0741521419301818 Quantitation of bivalirudin, a novel anticoagulant peptide, in human plasma by LC-MS/MS: method development, validation and application to XJ Li, YT Sun, L Yin, XJ Zhang, Y Yang - Journal of , 2013 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S2095177912001220 Bivalirudin inhibits periprocedural platelet function and tissue factor expression of human smooth muscle cells W Pepke, A Eisenreich, M Jaster, Y Ayral - Cardiovascular , 2013 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1111/j.1755-5922.2011.00305.x Bivalirudin decreases NO bioavailability by vascular immobilization of myeloperoxidase V Rudolph, TK Rudolph, FJ Schopfer , G Bonacci - of Pharmacology and , 2008 - ASPEThttps://jpet.aspetjournals.org/content/327/2/324.short Pharmacology and clinical use of bivalirudin TM Sciulli, VF Mauro - Annals of Pharmacotherapy, 2002 - journals.sagepub.comhttps://journals.sagepub.com/doi/abs/10.1345/aph.1A197 Bivalirudin: a review TE Warkentin, A Koster - Expert Opinion on Pharmacotherapy, 2005 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1517/14656566.6.8.1349 Bivalirudin TE Warkentin, A Greinacher - Thrombosis and , 2008 - thieme-connect.comhttps://www.thieme-connect.com/products/ejournals/abstract/10.1160/TH07-10-0644 Bivalent direct thrombin inhibitors: hirudin and bivalirudin TE Warkentin - Best Practice & Research Clinical Haematology, 2004 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S1521692604000039 Influence of bivalirudin on tissue factor-triggered coagulation T Orfeo, KE Brummel-Ziedins - Blood coagulation & , 2007 - journals.lww.comhttps://journals.lww.com/bloodcoagulation/FullText/2007/07000/Influence_of_bivalirudin_on_tissue.4.aspx Bivalirudin in percutaneous coronary intervention SJ Lehman, DP Chew - Vascular Health and Risk Management, 2006 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.2147/vhrm.s24357 Bivalirudin: a new generation antithrombotic drug R Scatena - Expert Opinion on Investigational Drugs, 2000 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1517/13543784.9.5.1119 Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender R Robson, H White, P Aylward - Clinical Pharmacology , 2002 - Wiley Online Libraryhttps://ascpt.onlinelibrary.wiley.com/doi/abs/10.1067/mcp.2002.124522 Antibodies against lepirudin are polyspecific and recognize epitopes on bivalirudin P Eichler, N Lubenow , U Strobel, A Greinacher - Blood, 2004 - ashpublications.orghttps://ashpublications.org/blood/article-abstract/103/2/613/17854 Storage stability of bivalirudin: hydrophilic versus lipophilic solutions O Zupančič , JA Griessinger, HT Lam - Journal of , 2017 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0022354917300229 Bivalirudin: pharmacology and clinical applications NW Shammas - Cardiovascular drug reviews, 2005 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1111/j.1527-3466.2005.tb00177.x Distinct effects of unfractionated heparin versus bivalirudin on circulating angiogenic peptides NK Kapur, C Shenoy , AA Yunis, NN Mohammad - PLoS , 2012 - journals.plos.orghttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0034344 Bivalirudin: in patients with ST-segment elevation myocardial infarction MP Curran - Drugs, 2010 - Springerhttps://link.springer.com/article/10.2165/11205120-000000000-00000 Bivalirudin in percutaneous coronary intervention MF Caron, GR McKendall - American journal of health-system , 2003 - academic.oup.comhttps://academic.oup.com/ajhp/article-abstract/60/18/1841/5143009 Clinical pharmacology of bivalirudin MD Reed , D Bell - : The Journal of Human Pharmacology and , 2002 - Wiley Online Libraryhttps://accpjournals.onlinelibrary.wiley.com/doi/abs/10.1592/phco.22.10.105S.33616 Bivalirudin: a review of its use in patients undergoing percutaneous coronary intervention MD Moen, GM Keating, K Wellington - Drugs, 2005 - Springerhttps://link.springer.com/article/10.2165/00003495-200565130-00010 Bivalirudin during percutaneous coronary intervention in acute coronary syndromes M Laine , G Lemesle , T Dabry, V Panagides - Expert opinion on , 2019 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1080/14656566.2018.1551361 Bivalirudin in acute coronary syndromes M Galli , M Bernardi , L Ortega-Paz , R Nerla - Expert Review of , 2023 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1080/14779072.2023.2273902 Safety of bivalirudin in patients with coronary artery disease M Abdel-Wahab, G Richardt - Expert Opinion on Drug Safety, 2012 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1517/14740338.2012.628312 , reverse phase ultra-high performance liquid chromatographic method for related substances of a therapeutic peptide (bivalirudin trifluoroacetate) using the quality by KYK Kumar, VR Dama, C Suchitra, TC Maringanti - Analytical methods, 2020 - pubs.rsc.orghttps://pubs.rsc.org/en/content/articlehtml/2020/ay/c9ay01998g Development of a Novel Separation Technique by High Performance Liquid Chromatography for the Determination of Bivalirudin KMM Gulzar, S Atul, S Surana - Journal of analytical chemistry, 2019 - Springerhttps://link.springer.com/article/10.1134/S1061934819100071 Liquid chromatography-high resolution mass spectrometry for peptide drug quality control K Zeng, I Geerlof-Vidavisky, A Gucinski , X Jiang - The AAPS Journal, 2015 - Springerhttps://link.springer.com/article/10.1208/s12248-015-9730-z Bivalirudin: an anticoagulant for acute coronary syndromes and coronary interventions HD White, DP Chew - Expert Opinion on Pharmacotherapy, 2002 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1517/14656566.3.6.777 MMP9-sensitive polymers mediate environmentally-responsive bivalirudin release and thrombin inhibition DS Chu, DL Sellers , MJ Bocek , AE Fischedick - Biomaterials , 2015 - pubs.rsc.orghttps://pubs.rsc.org/en/content/articlehtml/2015/bm/c4bm00259h Bivalirudin, a bivalent, thrombin specific anticoagulant as an alternative to heparin in interventional procedures DP Chew - Hamostaseologie, 2002 - thieme-connect.comhttps://www.thieme-connect.com/products/ejournals/html/10.1055/s-0037-1619549 Clinical outcomes of bivalirudin for ischemic heart disease DF Kong, EJ Topol , JA Bittl, HD White, P Théroux - Circulation, 1999 - Am Heart Assochttps://www.ahajournals.org/doi/abs/10.1161/01.cir.100.20.2049 Bivalirudin: a review of the pharmacology and clinical application DA Van De Car, SV Rao, EM Ohman - Expert review of , 2010 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1586/erc.10.158 Liquid chromatography method for determination of bivalirudin in human plasma and urine using automated ortho-phthalaldehyde derivatization and fluorescence D Farthing , T Larus, I Fakhry, T Gehr, J Prats - of Chromatography B, 2004 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S157002320301016X Bivalirudin: a review of its potential place in the management of acute coronary syndromes CI Carswell, GL Plosker - Drugs, 2002 - Springerhttps://link.springer.com/article/10.2165/00003495-200262050-00008 Bivalirudin is a dual inhibitor of thrombin and collagen-dependent platelet activation in patients undergoing percutaneous coronary intervention C Kimmelstiel, P Zhang, NK Kapur - Circulation , 2011 - Am Heart Assochttps://www.ahajournals.org/doi/abs/10.1161/circinterventions.110.959098 Safety and effectiveness of bivalirudin in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis AH Ahmad Hamdi, AF Dali , TH Mat Nuri - Frontiers in , 2017 - frontiersin.orghttps://www.frontiersin.org/articles/10.3389/fphar.2017.00410/full Bivalirudin monitored with the ecarin clotting time for anticoagulation during cardiopulmonary bypass A Koster, D Chew, M Grundel, M Bauer - Anesthesia & , 2003 - journals.lww.comhttps://journals.lww.com/anesthesia-analgesia/FullText/2003/02000/Bivalirudin_Monitored_with_the_Ecarin_Clotting.15.aspx

Aviso:
Nuestros productos están destinados únicamente para uso en laboratorio. Para cualquier otro uso, por favor contáctenos.
Marca:
Biosynth
Almacenamiento de larga duración:
Notas:

Propiedades químicas

MDL:
Punto de fusión:
Punto de ebullición:
Punto de inflamabilidad:
Densidad:
Concentración:
EINECS:
Merck:
Código HS:

Información de peligrosidad

Número UN:
Cantidad exceptuada (EQ):
Clase:
Frases H:
Frases P:
Prohibido volar:
Información de peligrosidad:
Grupo de empaquetado:
Cantidad limitada (LQ):

Consulta técnica sobre: 3D-PP49896 Bivalirudin

Use el carrito para solicitar presupuestos o pedidos

Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.

* Campos obligatorios
¡Bienvenido a CymitQuimica!Utilizamos cookies para mejorar su visita. No incluimos publicidad.

Consulte nuestra Política de Cookies para obtener más información o ajuste sus preferencias en "Configurar".